Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Rapporto sulle azioni

Cap. di mercato: US$8.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cerevel Therapeutics Holdings Gestione

Gestione criteri di controllo 2/4

Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of 1.17 years. total yearly compensation is $32.32M, comprised of 1.2% salary and 98.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $10.98M. The average tenure of the management team and the board of directors is 3.7 years and 5.4 years respectively.

Informazioni chiave

Ron Renaud

Amministratore delegato

US$32.3m

Compenso totale

Percentuale dello stipendio del CEO1.2%
Mandato del CEO1.2yrs
Proprietà del CEO0.1%
Durata media del management3.7yrs
Durata media del Consiglio di amministrazione5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ron Renaud rispetto agli utili di Cerevel Therapeutics Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2024n/an/a

-US$460m

Dec 31 2023US$32mUS$375k

-US$433m

Compensazione vs Mercato: Ron's total compensation ($USD32.32M) is above average for companies of similar size in the US market ($USD8.50M).

Compensazione vs guadagni: Insufficient data to compare Ron's compensation with company performance.


AMMINISTRATORE DELEGATO

Ron Renaud (55 yo)

1.2yrs

Mandato

US$32,322,358

Compensazione

Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
N. Coles
Executive Chairman5.8yrsUS$31.98m0.0086%
$ 702.8k
Ronald Renaud
President1.2yrsUS$32.32m0.13%
$ 11.0m
Susan Altschuller
Chief Financial Officer1.3yrsUS$4.63m0.0093%
$ 760.2k
Mark Bodenrader
Senior VP of Finance & Chief Accounting Officer4.9yrsUS$1.21m0.0097%
$ 797.0k
John Renger
Chief Scientific Officer5.3yrsUS$3.45m0.0035%
$ 286.7k
Ramiro Sanchez
Chief Medical Officer5.6yrsUS$4.13m0.0080%
$ 659.4k
Paul Burgess
Chief Business Development & Strategic Operations Officer1.2yrsUS$3.55m0.025%
$ 2.1m
Matthew Calistri
Vice President of Investor Relationsno dataNessun datoNessun dato
Scott Akamine
Chief Legal Officer & Corporate Secretary3.3yrsUS$3.19m0.0040%
$ 325.2k
Kenneth DiPietro
Chief Human Resources Officer5.3yrsNessun dato0.014%
$ 1.1m
Kathleen Tregoning
Chief Corporate Affairs Officer & Head of Commercial Strategy4.1yrsUS$3.92m0.0059%
$ 479.2k

3.7yrs

Durata media

54yo

Età media

Gestione esperta: CERE's management team is considered experienced (3.7 years average tenure).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
N. Coles
Executive Chairman5.8yrsUS$31.98m0.0086%
$ 702.8k
Ronald Renaud
President1.2yrsUS$32.32m0.13%
$ 11.0m
Gabrielle Greene-Sulzberger
Independent Director5.2yrsUS$513.93k0.027%
$ 2.2m
Marijn Dekkers
Independent Director5.9yrsUS$486.49k0.017%
$ 1.4m
Deval Patrick
Independent Director3.6yrsUS$485.48k0.0018%
$ 147.4k
Norbert Riedel
Lead Independent Director5.7yrsUS$564.65k0.025%
$ 2.1m
Christopher Gordon
Independent Director5.9yrsUS$501.43k0.0018%
$ 147.4k
Adam Koppel
Independent Director5.9yrsUS$504.65k0.0018%
$ 147.4k
Douglas Giordano
Independent Director5.9yrsUS$505.21k0.0018%
$ 147.4k
Ruth McKernan
Independent Director3.7yrsUS$485.48k0%
$ 0
Suneet Varma
Independent Director2.2yrsNessun datoNessun dato
Deborah Baron
Independent Director3.6yrsNessun datoNessun dato

5.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: CERE's board of directors are considered experienced (5.4 years average tenure).